Quality of medicine manufactured in Poland 2013-2021
In 2021, 63 percent of Poles rated the quality of Polish medicines high, an increase of 18 percentage points compared to 2013.
Quality assessment of drugs manufactured in Poland from 2013 to 2021
Source
In cooperation with
Release date
April 2022
More information
Region
Poland
Survey time period
2013 to 2021
Number of respondents
1041*
Age group
18 and over
Method of interview
Computer-assisted web interviews (CAWI)
Supplementary notes
*Count of people taking part in a survey:
2019 - N= 1000
2013- N= 987
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 5 people
$959 USD
per month, billed annually
1
- Free + Premium Statistics
- Reports
- Market Insights
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Pharmaceutical market worldwide
Overview
6
- Premium Statistic Pharmaceutical market: worldwide revenue 2001-2023
- Premium Statistic World pharmaceutical sales 2020-2023 by region
- Premium Statistic World pharmaceutical market distribution by submarket 2014-2023
- Premium Statistic Revenues of top 10 global pharmaceutical markets 2023
- Basic Statistic Top pharmaceutical products by sales worldwide 2023
- Basic Statistic AI readiness of big pharma companies 2023
Segments
6
- Basic Statistic Top therapeutic areas by global pharmaceutical sales 2023
- Basic Statistic Growth rate of top therapeutic areas 2023
- Basic Statistic Percentage of global pharmaceutical sales by technology 2016-2030
- Basic Statistic Projection of global revenue for orphan prescription drugs 2016-2028
- Basic Statistic Generic drugs market size worldwide 2023-2033
- Premium Statistic Revenue of the OTC pharmaceuticals industry worldwide 2018-2029
Companies
8
- Premium Statistic Top 50 pharmaceutical companies - Rx sales and R&D spending 2023
- Premium Statistic Top 10 biotech and pharmaceutical companies based on market cap 2024
- Premium Statistic Johnson & Johnson revenue 2005-2023
- Basic Statistic AbbVie revenue 2010-2023
- Premium Statistic Novartis' revenue 2007-2023
- Premium Statistic Merck & Co. revenue 2006-2023
- Premium Statistic Eli Lilly total revenue 2007-2023
- Basic Statistic Pharma company ranking based on access to medicine in developing countries 2024
R&D, patents, new products
7
- Premium Statistic Total global pharmaceutical R&D spending 2014-2030
- Premium Statistic Patent expiration risk for total worldwide global Rx drug revenue 2024-2030
- Basic Statistic Worldwide Rx drug revenue - market at risk from patent expiration 2024-2030
- Premium Statistic Pharmaceutical industry - number of new substances 1998-2023
- Basic Statistic Pharma companies worldwide with active R&D pipelines 2001-2024
- Premium Statistic Number of novel drugs approved annually by CDER 2008-2023
- Basic Statistic Projected most valuable R&D projects based on net present value 2023
Outlook
6
- Premium Statistic World pharmaceutical sales by region forecast 2027
- Premium Statistic Global spending on medicines 2010-2027
- Basic Statistic Top global biopharma drugs by lifetime sales up to 2028
- Basic Statistic Sales forecast of top pharmaceutical companies worldwide 2028
- Premium Statistic Sales forecast of top selling drugs worldwide 2028
- Basic Statistic Global artificial intelligence (AI) drug discovery market forecast 2023-2032
Review: COVID-19 response
6
- Basic Statistic Biotechs: duration of COVID-19 response compared to previous health threats 2003-2019
- Premium Statistic BARDA funding for the development of COVID-19 vaccines in the U.S. 2021
- Premium Statistic Shareholdings at select COVID-19 vaccine companies by investor 2021
- Premium Statistic Top companies by COVID-19 treatment vaccines in development June 2022
- Basic Statistic Comparison of select COVID-19 vaccines 2022, by efficacy
- Basic Statistic Distribution of COVID-19 vaccines worldwide by mechanism and phase 2022
Further related statistics
10
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Pfizer's ad spending 2006-2023
- Merck & Co cash dividends declared 2006-2023
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co total assets 2019-2023
- AstraZeneca's expenditure on research and development 2006-2023
- Johnson & Johnson employees 2004-2023
- Sales of Johnson & Johnson worldwide 2011-2023, by segment
- Sales of Johnson & Johnson 2006-2023 by region
Further Content: You might find this interesting as well
Statistics
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Pfizer's ad spending 2006-2023
- Merck & Co cash dividends declared 2006-2023
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co total assets 2019-2023
- AstraZeneca's expenditure on research and development 2006-2023
- Johnson & Johnson employees 2004-2023
- Sales of Johnson & Johnson worldwide 2011-2023, by segment
- Sales of Johnson & Johnson 2006-2023 by region
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 5 people
$959 USD
per month, billed annually
1
- Free + Premium Statistics
- Reports
- Market Insights
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Civitta Polska. (April 5, 2022). Quality assessment of drugs manufactured in Poland from 2013 to 2021 [Graph]. In Statista. Retrieved November 22, 2024, from https://www.statista.com/statistics/1301744/poland-quality-of-medicine-manufactured/
Civitta Polska. "Quality assessment of drugs manufactured in Poland from 2013 to 2021." Chart. April 5, 2022. Statista. Accessed November 22, 2024. https://www.statista.com/statistics/1301744/poland-quality-of-medicine-manufactured/
Civitta Polska. (2022). Quality assessment of drugs manufactured in Poland from 2013 to 2021. Statista. Statista Inc.. Accessed: November 22, 2024. https://www.statista.com/statistics/1301744/poland-quality-of-medicine-manufactured/
Civitta Polska. "Quality Assessment of Drugs Manufactured in Poland from 2013 to 2021." Statista, Statista Inc., 5 Apr 2022, https://www.statista.com/statistics/1301744/poland-quality-of-medicine-manufactured/
Civitta Polska, Quality assessment of drugs manufactured in Poland from 2013 to 2021 Statista, https://www.statista.com/statistics/1301744/poland-quality-of-medicine-manufactured/ (last visited November 22, 2024)
Quality assessment of drugs manufactured in Poland from 2013 to 2021 [Graph], Civitta Polska, April 5, 2022. [Online]. Available: https://www.statista.com/statistics/1301744/poland-quality-of-medicine-manufactured/